NCT04227210View on ClinicalTrials.gov

Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 14, 2020

Primary Completion Date

August 27, 2020

Study Completion Date

August 27, 2020

Conditions
Respiratory Syncytial Virus Infections
Interventions
BIOLOGICAL

RSV vaccine MV-012-968 (dosage #1)

Single dose administered intranasally on Day 1

BIOLOGICAL

RSV vaccine MV-012-968 (dosage #2)

Single dose administered intranasally on Day 1

Trial Locations (1)

66219

Johnson County Clin-Trials, Lenexa

Sponsors
All Listed Sponsors
lead

Meissa Vaccines, Inc.

INDUSTRY

NCT04227210 - Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults | Biotech Hunter | Biotech Hunter